This study evaluates EEG changes as a potential early biomarker for epilepsy in patients with CLN3 disease, suggesting a new approach to monitoring disease progression.
Background/Purpose: Juvenile neuronal ceroid lipofuscinosis or CLN3 disease is a pediatric neurodegenerative disorder characterized by visual loss, epilepsy, and psychomotor deterioration. No approved treatment for CLN3 is currently available. Patients may present with significant phenotypic variability, which complicates the evaluation of potential therapies. Biomarkers as surrogates to measure disease progression are needed to assess the efficacy of experimental therapies. This study evaluates EEG findings as a potential early biomarker for CLN3 disease.
No takes yet. Share an insight, caveat, or question.
Finter et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: